The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Harry ErbaDuring the Society of Hematologic Oncology (SOHO) 2023 Congress, the AML Hub was pleased to speak to Harry Erba, Duke University, Durham, US. We asked, What are the latest updates from the phase III QuANTUM-First trial?
What are the latest updates from the phase III QuANTUM-First trial?
Erba discusses the QuANTUM-First trial (NCT02668653) assessing the addition of quizartinib vs placebo to standard chemotherapy and continuation therapy in adult patients aged 18–75 years with newly diagnosed FLT3-internal tandem duplication mutated acute myeloid leukemia. He continues by delving into response rates, survival outcomes, and safety data from the trial; outlining the factors that could influence responses. Erba compares the findings of QuANTUM-First with the phase III RATIFY trial (NCT00651261), which investigated the addition of midostaurin to standard chemotherapy in patients with FLT3-mutated AML.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content